Aripiprazole-induced quasi-neuroleptic malignant syndrome: two case reports.
Atypical antipsychotic
Creatine kinase
Neuroleptic malignant syndrome
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
18 Apr 2024
18 Apr 2024
Historique:
received:
06
12
2023
accepted:
13
03
2024
medline:
19
4
2024
pubmed:
18
4
2024
entrez:
17
4
2024
Statut:
epublish
Résumé
Significant elevation of creatine kinase levels (above three digits) and leucocytosis in the absence of muscle rigidity, tremors, or autonomic dysfunction can pose a real challenge in the context of antipsychotic treatment as an early herald of neuroleptic malignant syndrome. We present here two cases of adult male patients of Black British heritage, ages 51 years and 28 years, respectively. Both received a diagnosis of schizoaffective disorder and presented with massive increase of creatine kinase blood level after aripiprazole depot administration, one with pernicious increase associated with silent neuroleptic malignant syndrome, and the second with asymptomatic benign enzyme elevation. Though aripiprazole use is less likely to cause neuroleptic malignant syndrome, on rare occasions it can produce massive symptomatic or asymptomatic increase in serum creatine kinase enzyme levels, raising the need for close monitoring, especially at the initial doses of the drug.
Sections du résumé
BACKGROUND
BACKGROUND
Significant elevation of creatine kinase levels (above three digits) and leucocytosis in the absence of muscle rigidity, tremors, or autonomic dysfunction can pose a real challenge in the context of antipsychotic treatment as an early herald of neuroleptic malignant syndrome.
CASE PRESENTATION
METHODS
We present here two cases of adult male patients of Black British heritage, ages 51 years and 28 years, respectively. Both received a diagnosis of schizoaffective disorder and presented with massive increase of creatine kinase blood level after aripiprazole depot administration, one with pernicious increase associated with silent neuroleptic malignant syndrome, and the second with asymptomatic benign enzyme elevation.
CONCLUSION
CONCLUSIONS
Though aripiprazole use is less likely to cause neuroleptic malignant syndrome, on rare occasions it can produce massive symptomatic or asymptomatic increase in serum creatine kinase enzyme levels, raising the need for close monitoring, especially at the initial doses of the drug.
Identifiants
pubmed: 38632633
doi: 10.1186/s13256-024-04508-0
pii: 10.1186/s13256-024-04508-0
pmc: PMC11025188
doi:
Substances chimiques
Aripiprazole
82VFR53I78
Antipsychotic Agents
0
Creatine Kinase
EC 2.7.3.2
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
190Informations de copyright
© 2024. The Author(s).
Références
Arq Gastroenterol. 2019 Aug 13;56(2):155-159
pubmed: 31460579
J Child Adolesc Psychopharmacol. 2014 Dec;24(10):536-42
pubmed: 25387323
Health Psychol Res. 2022 Aug 20;10(3):37530
pubmed: 35999974
Drugs R D. 2015 Mar;15(1):45-62
pubmed: 25578944
Psychopharmacology (Berl). 2014 Nov;231(22):4255-70
pubmed: 25319963
SAGE Open Med Case Rep. 2022 Mar 15;10:2050313X221085096
pubmed: 35308054
Am J Ther. 2022 Nov-Dec 01;29(6):e653-e655
pubmed: 32251004
BJPsych Open. 2020 Dec 04;7(1):e4
pubmed: 33272348